

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	5.9	84.2	(27.1-196.5)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.5	91.8	(33.5-199.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	23	21.7	105.9	(67.1-158.8)
Female	0	0.1	nc	(nc-nc)	Female	11	18.7	58.7	(29.3-105.1)
<u>Lung and Bronchus</u>									
Male	5	2.9	169.7	(54.7-396.0)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	21	20.7	101.2	(62.6-154.7)	Female	1	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	6	8.0	74.7	(27.3-162.6)	<u>Ovary</u>				
Female	6	6.6	91.4	(33.4-198.9)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	19	21.0	90.4	(54.4-141.2)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.2	nc	(nc-nc)	Male	59	73.2	80.6	(61.3-103.9)
Female	0	0.3	nc	(nc-nc)	Female	71	65.5	108.5	(84.7-136.8)
<u>Lung and Bronchus</u>									
Male	6	9.7	62.0	(22.6-135.0)					
Female	18	8.1	223.2	(132.2-352.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

265

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	42.5	110.6	(81.2-147.0)	Male	21	23.8	88.2	(54.6-134.9)
Female	17	17.2	99.0	(57.6-158.5)	Female	29	21.8	133.0	(89.1-191.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.2	nc	(nc-nc)	Male	7	6.4	109.3	(43.8-225.2)
Female	3	7.4	nc	(nc-nc)	Female	5	5.5	91.5	(29.5-213.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	22	21.9	100.6	(63.0-152.3)
Female	165	169.5	97.4	(83.1-113.4)	Female	28	22.2	126.2	(83.9-182.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.7	116.1	(53.0-220.5)	Male	16	15.6	102.5	(58.5-166.4)
<u>Colon / Rectum</u>					Female	12	8.4	143.0	(73.8-249.8)
Male	75	63.3	118.5	(93.2-148.5)	<u>Ovary</u>				
Female	68	68.4	99.5	(77.3-126.1)	Female	18	18.5	97.5	(57.8-154.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.7	102.8	(51.2-184.0)	Male	15	11.9	125.7	(70.3-207.3)
Female	5	3.3	149.6	(48.2-349.1)	Female	16	14.6	109.6	(62.6-178.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.6	nc	(nc-nc)	Male	156	163.5	95.4	(81.0-111.6)
Female	5	3.4	147.7	(47.6-344.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	10.8	157.2	(91.5-251.7)
Male	20	17.6	113.4	(69.2-175.1)	Female	12	7.4	162.6	(83.9-284.0)
Female	6	12.3	48.7	(17.8-106.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.6	76.1	(24.5-177.5)
Male	8	6.9	115.4	(49.7-227.5)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	8	5.1	156.8	(67.5-309.0)
<u>Leukemia</u>					Female	15	18.5	81.2	(45.4-134.0)
Male	19	13.5	140.3	(84.4-219.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	12.3	138.7	(80.7-222.1)	Female	29	34.9	83.0	(55.6-119.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.6	70.0	(25.6-152.3)	Male	601	560.6	107.2	(98.8-116.1)
Female	2	3.5	nc	(nc-nc)	Female	625	584.3	107.0	(98.7-115.7)
<u>Lung and Bronchus</u>									
Male	99	78.9	125.4	(101.9-152.7)					
Female	97	80.6	120.3	(97.6-146.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

266

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.3	144.0	(74.3-251.6)	Male	0	5.0	nc	(nc-nc)
Female	8	2.9	277.9	(119.7-547.7)	Female	2	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	24	32.0	74.9	(48.0-111.5)	Female	5	3.8	131.4	(42.3-306.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	18	12.8	141.1	(83.6-223.1)	<u>Ovary</u>				
Female	11	11.1	99.1	(49.4-177.3)	Female	4	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	2.2	312.0	(125.0-642.9)	Male	4	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	30	34.9	85.8	(57.9-122.6)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	5	2.2	226.3	(72.9-528.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	3.5	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	6	6.8	88.5	(32.3-192.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.8	nc	(nc-nc)	Male	123	115.7	106.3	(88.3-126.8)
Female	0	0.6	nc	(nc-nc)	Female	110	104.2	105.5	(86.7-127.2)
<u>Lung and Bronchus</u>									
Male	21	15.9	132.1	(81.7-201.9)					
Female	23	14.2	161.8	(102.5-242.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

267

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.9	135.6	(58.4-267.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	19	19.4	98.1	(59.0-153.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	2.9	175.3	(56.5-409.1)					

Female	2	1.6	nc	(nc-nc)	Female	7	11.5	61.1	(24.5-125.9)
--------	---	-----	----	---------	--------	---	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

268

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	23.2	116.5	(76.7-169.4)	Male	25	12.8	194.7	(126.0-287.5)
Female	10	8.2	122.3	(58.6-224.9)	Female	22	10.5	210.3	(131.8-318.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.5	178.4	(76.8-351.5)	Male	8	3.5	228.3	(98.3-449.9)
Female	6	3.6	164.4	(60.0-357.8)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	19	11.9	160.1	(96.3-250.0)
Female	105	85.3	123.0	(100.6-148.9)	Female	11	10.6	104.0	(51.8-186.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	6	8.7	68.9	(25.2-150.0)
<u>Colon / Rectum</u>					Female	5	4.1	122.6	(39.5-286.1)
Male	31	34.6	89.5	(60.8-127.1)	<u>Ovary</u>				
Female	35	32.3	108.5	(75.5-150.8)	Female	12	9.1	131.7	(68.0-230.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.9	118.5	(47.5-244.2)	Male	8	6.6	122.0	(52.5-240.5)
Female	0	1.6	nc	(nc-nc)	Female	11	6.9	159.3	(79.4-285.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	121	89.6	135.0	(112.0-161.3)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.9	nc	(nc-nc)
Male	11	9.7	112.8	(56.3-201.9)	Female	3	3.5	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.8	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.9	67.7	(24.7-147.3)
Male	11	7.3	149.7	(74.6-267.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	5.9	256.3	(143.3-422.8)	Female	11	17.5	62.9	(31.4-112.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	4	4.7	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					

Lung and Bronchus

Male	44	43.3	101.7	(73.9-136.6)
Female	32	39.0	82.1	(56.2-115.9)

All Sites / Types

Male	360	305.5	117.8	(106.0-130.7)
Female	322	284.7	113.1	(101.1-126.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

269

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	35.9	133.7	(98.6-177.3)	Male	17	19.0	89.6	(52.2-143.5)
Female	18	13.1	137.4	(81.4-217.1)	Female	9	15.3	58.8	(26.8-111.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.2	96.3	(35.2-209.5)	Male	3	5.4	nc	(nc-nc)
Female	3	5.3	nc	(nc-nc)	Female	0	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	26	17.6	148.0	(96.6-216.8)
Female	115	127.3	90.3	(74.6-108.4)	Female	19	16.5	115.1	(69.3-179.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.3	93.7	(30.2-218.6)	Male	15	12.9	116.7	(65.3-192.5)
<u>Colon / Rectum</u>					Female	7	6.3	111.6	(44.7-230.0)
Male	54	53.1	101.6	(76.4-132.6)	<u>Ovary</u>				
Female	56	51.2	109.3	(82.6-142.0)	Female	8	13.8	58.1	(25.0-114.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	9.0	99.7	(45.5-189.3)	Male	10	10.1	99.2	(47.5-182.4)
Female	4	2.5	nc	(nc-nc)	Female	3	11.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	136	140.2	97.0	(81.4-114.7)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.0	88.7	(38.2-174.7)
Male	14	14.6	95.9	(52.4-161.0)	Female	5	5.4	91.8	(29.6-214.1)
Female	7	9.3	75.1	(30.1-154.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.8	158.5	(57.9-345.0)
Male	9	5.9	153.7	(70.1-291.8)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	3.8	132.9	(42.8-310.1)
<u>Leukemia</u>					Female	10	12.1	82.4	(39.5-151.6)
Male	12	10.8	111.3	(57.5-194.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.8	113.3	(54.3-208.4)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	8	7.1	113.4	(48.8-223.4)					
Female	0	2.6	nc	(nc-nc)	Female	36	26.9	133.9	(93.8-185.4)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	69	66.9	103.1	(80.2-130.5)	Male	494	467.0	105.8	(96.7-115.5)
Female	73	62.5	116.8	(91.6-146.9)	Female	426	436.4	97.6	(88.6-107.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

270

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)

Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	1.5	nc	(nc-nc)	Male	7	10.9	64.2	(25.7-132.3)
Female	2	1.1	nc	(nc-nc)	Female	10	8.3	119.8	(57.4-220.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

271

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.3	67.4	(37.7-111.2)	Male	17	12.3	138.5	(80.6-221.7)
Female	5	8.0	62.2	(20.0-145.2)	Female	12	9.9	121.4	(62.6-212.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	11.2	89.1	(42.7-163.9)
Female	88	82.7	106.5	(85.4-131.2)	Female	6	10.2	58.6	(21.4-127.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	12	8.6	140.0	(72.3-244.6)
<u>Colon / Rectum</u>					Female	4	4.0	nc	(nc-nc)
Male	30	33.4	89.9	(60.6-128.3)	<u>Ovary</u>				
Female	30	31.3	95.8	(64.6-136.8)	Female	7	8.8	79.3	(31.8-163.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.8	103.5	(37.8-225.4)	Male	6	6.4	94.4	(34.5-205.5)
Female	3	1.6	nc	(nc-nc)	Female	7	6.7	103.8	(41.6-214.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	94	91.4	102.8	(83.1-125.8)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	5.6	142.6	(61.4-281.0)
Male	8	9.6	83.5	(35.9-164.5)	Female	2	3.3	nc	(nc-nc)
Female	2	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

Leukemia

Male	5	6.9	72.5	(23.4-169.2)
Female	8	5.6	143.4	(61.7-282.5)

Liver and Intrahepatic Bile Ducts

Male	4	4.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)

Lung and Bronchus

Male	48	42.4	113.2	(83.5-150.1)
Female	35	38.6	90.6	(63.1-126.1)

Thyroid

Male	2	2.5	nc	(nc-nc)
Female	6	8.2	73.5	(26.9-160.1)

Uteri Corpus and Uterus, NOS

Female	17	17.4	97.9	(57.0-156.8)
--------	----	------	------	--------------

All Sites / Types

Male	300	299.1	100.3	(89.3-112.3)
Female	266	276.2	96.3	(85.1-108.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

272

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	15.8	152.0	(97.4-226.2)	Male	9	8.9	100.9	(46.0-191.5)
Female	6	5.1	117.2	(42.8-255.1)	Female	5	6.9	72.8	(23.5-169.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	8.2	73.6	(26.9-160.1)
Female	76	56.0	135.8	(107.0-170.0)	Female	5	6.7	74.2	(23.9-173.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	5	6.2	80.4	(25.9-187.6)
<u>Colon / Rectum</u>					Female	5	2.6	190.1	(61.2-443.5)
Male	28	23.8	117.7	(78.2-170.1)	<u>Ovary</u>				
Female	13	20.0	65.1	(34.6-111.4)	Female	5	5.9	84.3	(27.2-196.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.1	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	57	63.9	89.2	(67.6-115.6)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	4.0	275.1	(137.1-492.2)
Male	7	6.8	102.3	(41.0-210.8)	Female	1	2.1	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>									

Male	4	2.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	5.0	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	5	3.7	136.6	(44.0-318.7)	Female	5	6.0	83.5	(26.9-194.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.3	nc	(nc-nc)	Female	11	11.5	95.4	(47.5-170.7)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	33	29.9	110.4	(76.0-155.1)	Male	213	212.7	100.1	(87.1-114.5)
Female	31	25.0	123.8	(84.1-175.7)	Female	194	183.2	105.9	(91.5-121.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

273

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	17.3	92.6	(52.9-150.5)	Male	15	10.4	144.5	(80.8-238.4)
Female	4	5.9	nc	(nc-nc)	Female	13	8.4	155.3	(82.6-265.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	134.6	(43.4-314.1)	Male	3	2.7	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	15	9.4	160.2	(89.6-264.3)
Female	91	69.3	131.3	(105.7-161.2)	Female	7	7.8	89.2	(35.7-183.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.2	nc	(nc-nc)	Male	7	7.4	94.4	(37.8-194.6)
<u>Colon / Rectum</u>					Female	0	3.2	nc	(nc-nc)
Male	19	26.5	71.7	(43.1-112.0)	<u>Ovary</u>				
Female	27	23.1	116.8	(76.9-169.9)	Female	6	7.2	82.9	(30.3-180.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.7	nc	(nc-nc)	Male	8	5.0	158.6	(68.3-312.6)
Female	2	1.1	nc	(nc-nc)	Female	8	4.9	163.1	(70.2-321.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	64	71.2	89.9	(69.2-114.8)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.4	135.1	(49.3-294.0)
Male	2	7.9	nc	(nc-nc)					

Female	6	4.6	129.9	(47.4-282.8)
--------	---	-----	-------	--------------

Larynx

Male	2	3.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Leukemia

Male	6	5.7	104.8	(38.3-228.0)
Female	4	4.4	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	5	3.9	127.1	(41.0-296.6)
Female	1	1.2	nc	(nc-nc)

Lung and Bronchus

Male	29	32.8	88.4	(59.2-126.9)
Female	27	28.6	94.3	(62.1-137.3)

Female	2	2.4	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	4	2.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	3	2.3	nc	(nc-nc)
Female	13	7.5	172.6	(91.8-295.2)

Uteri Corpus and Uterus, NOS

Female	16	14.1	113.8	(65.0-184.7)
--------	----	------	-------	--------------

All Sites / Types

Male	233	239.1	97.5	(85.3-110.8)
Female	249	219.4	113.5	(99.8-128.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

274

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	4.5	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	12	15.2	78.9	(40.7-137.8)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	6.7	75.1	(24.2-175.2)	<u>Ovary</u>				
Female	4	5.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	15	18.0	83.5	(46.7-137.8)
Female	0	0.2	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	1	1.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

Larynx

Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	1	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Lung and Bronchus

Male	7	8.4	83.3	(33.4-171.5)
Female	5	7.2	69.3	(22.3-161.6)

Stomach

Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Testis

Male	1	0.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	0.5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	3.2	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	48	59.1	81.2	(59.9-107.6)
Female	38	50.6	75.1	(53.2-103.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

275

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.9	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	8	10.9	73.1	(31.5-144.1)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	12	5.0	238.4	(123.0-416.4)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	0	0.2	nc	(nc-nc)	Male	11	11.3	97.2	(48.5-174.0)
Female	0	0.2	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	6	2.2	268.6	(98.1-584.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	5.4	nc	(nc-nc)	Male	33	37.8	87.2	(60.0-122.5)
Female	4	5.5	nc	(nc-nc)	Female	47	38.9	120.7	(88.7-160.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

276

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	107.6	(34.7-251.2)	Male	5	2.7	184.4	(59.4-430.3)
Female	1	1.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	20	17.4	115.2	(70.3-177.9)	Female	2	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
					Female	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.1	84.1	(30.7-183.1)					
Female	6	5.5	109.3	(39.9-238.0)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)

Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	19.8	116.3	(73.7-174.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.8	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	4	3.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Male	61	64.5	94.6	(72.3-121.5)
Female	0	0.3	nc	(nc-nc)	Female	46	53.9	85.4	(62.5-113.9)
<u>Lung and Bronchus</u>									
Male	3	9.0	nc	(nc-nc)					
Female	4	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

277

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.4	94.2	(34.4-204.9)	Male	1	4.4	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	23	22.8	101.1	(64.1-151.7)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	10	10.0	100.3	(48.0-184.5)	<u>Ovary</u>				
Female	7	7.8	89.3	(35.8-184.0)	Female	2	2.4	nc	(nc-nc)

Esophagus

Male	5	1.8	283.9	(91.5-662.5)
Female	1	0.4	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	3.1	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)

Larynx

Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Leukemia

Male	2	2.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Lung and Bronchus

Male	16	12.3	129.7	(74.1-210.7)
Female	15	9.9	152.2	(85.1-251.0)

Pancreas

Male	1	1.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)

Prostate

Male	18	26.6	67.7	(40.1-106.9)
------	----	------	------	--------------

Stomach

Male	1	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Testis

Male	0	1.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	1.1	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	4.6	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	87	92.8	93.8	(75.1-115.7)
Female	69	73.8	93.5	(72.7-118.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

278

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	33.8	82.7	(55.0-119.6)	Male	13	19.5	66.8	(35.5-114.3)
Female	13	12.6	103.6	(55.1-177.1)	Female	11	16.4	67.3	(33.5-120.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.8	147.4	(70.6-271.1)	Male	3	5.2	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	18	17.7	101.5	(60.1-160.4)
Female	123	128.2	96.0	(79.7-114.5)	Female	18	16.3	110.4	(65.4-174.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	99.8	(36.4-217.2)	Male	5	13.0	38.5	(12.4-89.9)
<u>Colon / Rectum</u>					Female	6	6.2	96.5	(35.3-210.2)
					<u>Ovary</u>				

Male	39	50.8	76.7	(54.5-104.9)
Female	50	49.9	100.3	(74.4-132.2)

Esophagus

Male	2	8.7	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	2.8	nc	(nc-nc)
Female	5	2.3	216.0	(69.6-504.0)

Kidney & Renal Pelvis

Male	15	14.5	103.5	(57.9-170.7)
Female	4	9.2	nc	(nc-nc)

Larynx

Male	3	5.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)

Leukemia

Male	3	11.0	nc	(nc-nc)
Female	9	9.1	98.4	(44.9-186.8)

Liver and Intrahepatic Bile Ducts

Male	9	7.0	128.3	(58.5-243.5)
Female	2	2.5	nc	(nc-nc)

Lung and Bronchus

Male	53	62.9	84.3	(63.1-110.2)
Female	51	59.2	86.2	(64.1-113.3)

Female	10	13.8	72.5	(34.7-133.4)
--------	----	------	------	--------------

Pancreas

Male	8	9.6	83.2	(35.8-164.0)
Female	12	10.6	112.9	(58.3-197.2)

Prostate

Male	103	131.3	78.4	(64.0-95.1)
------	-----	-------	------	-------------

Stomach

Male	7	8.7	80.7	(32.3-166.3)
Female	2	5.4	nc	(nc-nc)

Testis

Male	6	5.1	118.6	(43.3-258.2)
------	---	-----	-------	--------------

Thyroid

Male	8	4.3	188.2	(81.0-370.9)
Female	15	14.1	106.5	(59.6-175.6)

Uteri Corpus and Uterus, NOS

Female	24	26.2	91.5	(58.6-136.2)
--------	----	------	------	--------------

All Sites / Types

Male	365	451.2	80.9	(72.8-89.6)
Female	397	434.6	91.3	(82.6-100.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

279

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	6	6.1	97.8	(35.7-212.8)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	0	0.7	nc	(nc-nc)

Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.0	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	5.4	110.4	(40.3-240.2)
Female	0	0.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.4	nc	(nc-nc)	Male	14	18.9	74.3	(40.6-124.6)
Female	0	2.0	nc	(nc-nc)	Female	13	17.6	74.0	(39.4-126.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

280

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	27.7	126.3	(88.0-175.7)	Male	8	14.1	56.6	(24.4-111.5)
Female	7	10.8	64.7	(25.9-133.3)	Female	12	11.6	103.8	(53.6-181.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.6	109.4	(35.3-255.4)	Male	2	4.1	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	13.2	83.0	(41.4-148.6)
Female	95	97.7	97.2	(78.7-118.9)	Female	22	13.3	165.0	(103.4-249.9)

Cervix Uteri

Female	4	3.9	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	37	40.7	90.9	(64.0-125.3)
Female	44	42.8	102.8	(74.7-138.1)

Esophagus

Male	6	6.9	87.6	(32.0-190.6)
Female	3	2.1	nc	(nc-nc)

Hodgkin Lymphoma

Male	3	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	13	11.0	118.6	(63.1-202.8)
Female	6	7.4	81.2	(29.6-176.7)

Larynx

Male	4	4.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

Leukemia

Male	10	8.1	123.0	(58.9-226.2)
Female	6	7.1	84.4	(30.8-183.7)

Liver and Intrahepatic Bile Ducts

Male	5	5.3	94.5	(30.5-220.6)
Female	1	2.1	nc	(nc-nc)

Lung and Bronchus

Male	55	51.5	106.8	(80.4-139.0)
Female	37	50.5	73.2	(51.6-101.0)

Oral Cavity & Pharynx

Male	12	9.5	126.1	(65.1-220.2)
Female	3	4.9	nc	(nc-nc)

Ovary

Female	10	10.7	93.3	(44.7-171.5)
--------	----	------	------	--------------

Pancreas

Male	12	7.7	155.7	(80.3-271.9)
Female	10	9.2	108.4	(51.9-199.4)

Prostate

Male	113	106.3	106.3	(87.6-127.8)
------	-----	-------	-------	--------------

Stomach

Male	11	6.9	159.0	(79.2-284.5)
Female	2	4.6	nc	(nc-nc)

Testis

Male	2	2.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	3	2.7	nc	(nc-nc)
Female	7	8.5	82.1	(32.9-169.3)

Uteri Corpus and Uterus, NOS

Female	23	20.7	111.2	(70.5-166.9)
--------	----	------	-------	--------------

All Sites / Types

Male	370	354.5	104.4	(94.0-115.6)
Female	324	345.5	93.8	(83.8-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

281

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	58.2	89.3	(66.7-117.1)	Male	27	36.5	74.0	(48.8-107.7)
Female	27	24.6	109.7	(72.3-159.6)	Female	20	35.3	56.7	(34.6-87.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	13.0	115.6	(64.7-190.7)	Male	5	8.9	55.9	(18.0-130.6)
Female	15	11.5	130.4	(72.9-215.1)	Female	8	7.8	103.1	(44.4-203.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	1	1.8	nc	(nc-nc)	Male	30	32.9	91.2	(61.5-130.2)
Female	211	244.9	86.2	(74.9-98.6)	Female	35	32.8	106.7	(74.3-148.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	12.7	102.3	(54.4-174.9)	Male	19	22.5	84.6	(50.9-132.0)
<u>Colon / Rectum</u>					Female	22	12.4	177.4	(111.2-268.7)
Male	77	88.0	87.5	(69.1-109.4)	<u>Ovary</u>				
Female	80	97.7	81.9	(64.9-101.9)	Female	17	27.0	63.0	(36.7-101.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	14.9	121.1	(71.7-191.4)	Male	16	16.5	97.2	(55.5-157.9)
Female	0	4.8	nc	(nc-nc)	Female	16	20.8	76.8	(43.9-124.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	7.9	76.2	(27.8-165.9)	Male	176	224.0	78.6	(67.4-91.1)
Female	7	6.7	103.7	(41.5-213.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	15.2	131.8	(80.5-203.6)
Male	27	25.2	107.2	(70.6-156.0)	Female	17	10.6	159.9	(93.1-256.0)
Female	11	17.7	62.0	(30.9-110.9)	<u>Testis</u>				
<u>Larynx</u>					Male	19	15.9	119.3	(71.8-186.3)
Male	12	9.6	124.7	(64.4-217.9)	<u>Thyroid</u>				
Female	2	3.0	nc	(nc-nc)	Male	9	8.9	101.3	(46.2-192.3)
<u>Leukemia</u>					Female	38	32.3	117.5	(83.2-161.3)
Male	22	20.4	108.1	(67.7-163.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	18.2	137.1	(88.7-202.4)	Female	48	50.1	95.8	(70.6-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	26	12.2	214.0	(139.7-313.5)	Male	748	798.5	93.7	(87.1-100.6)
Female	11	5.0	219.2	(109.3-392.3)	Female	811	856.7	94.7	(88.3-101.4)
<u>Lung and Bronchus</u>									
Male	121	108.4	111.6	(92.6-133.4)					
Female	121	115.1	105.2	(87.3-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	21.8	119.4	(78.0-175.0)	Male	12	11.1	107.8	(55.6-188.4)
Female	7	8.5	82.0	(32.8-168.9)	Female	16	9.8	163.4	(93.3-265.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	193.5	(77.5-398.6)	Male	2	3.2	nc	(nc-nc)

Female	4	3.4	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	12	10.5	114.8	(59.3-200.6)
Female	85	78.3	108.5	(86.7-134.2)	Female	16	10.7	148.9	(85.0-241.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	6	7.4	80.9	(29.5-176.1)
<u>Colon / Rectum</u>					Female	5	4.0	125.3	(40.4-292.5)
Male	32	31.9	100.2	(68.5-141.4)	<u>Ovary</u>				
Female	26	33.9	76.7	(50.1-112.4)	Female	11	8.7	126.4	(63.0-226.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.3	149.9	(64.5-295.4)	Male	6	6.0	99.3	(36.3-216.2)
Female	0	1.7	nc	(nc-nc)	Female	11	7.3	151.1	(75.3-270.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	92	81.5	112.9	(91.0-138.5)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.5	128.1	(51.3-263.9)
Male	10	8.5	117.3	(56.1-215.7)	Female	1	3.7	nc	(nc-nc)
Female	2	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	7	2.1	335.7	(134.5-691.6)
Male	2	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.8	nc	(nc-nc)
Male	2	6.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.9	119.0	(47.7-245.2)	Female	15	16.4	91.6	(51.2-151.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	295	276.2	106.8	(95.0-119.7)
Female	1	1.7	nc	(nc-nc)	Female	258	278.1	92.8	(81.8-104.8)
<u>Lung and Bronchus</u>									
Male	37	40.0	92.5	(65.1-127.5)					
Female	28	39.8	70.4	(46.8-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

283

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.3	94.2	(30.4-219.8)	Male	3	3.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)

Brain and Other Nervous System

Male	1	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Breast

Male	0	0.2	nc	(nc-nc)
Female	18	22.0	81.9	(48.5-129.4)

Cervix Uteri

Female	2	1.0	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	6	8.2	72.9	(26.6-158.8)
Female	5	7.3	68.5	(22.1-159.8)

Esophagus

Male	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	0	2.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)

Larynx

Male	0	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Leukemia

Male	4	1.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Lung and Bronchus

Male	9	10.1	89.5	(40.9-170.0)
Female	10	9.0	110.8	(53.0-203.8)

Multiple Myeloma

Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	4	3.0	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)

Oral Cavity & Pharynx

Male	2	2.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)

Ovary

Female	2	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	4	1.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)

Prostate

Male	25	22.3	112.3	(72.7-165.9)
------	----	------	-------	--------------

Stomach

Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

Testis

Male	0	0.8	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.8	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	4	4.5	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	74	74.7	99.1	(77.8-124.4)
Female	67	69.7	96.2	(74.5-122.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	9	7.4	121.0	(55.2-229.7)	Male	7	4.8	144.4	(57.9-297.5)
Female	1	2.3	nc	(nc-nc)	Female	5	3.9	129.1	(41.6-301.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	4	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.3	116.7	(37.6-272.2)
Female	55	30.2	182.1	(137.1-237.0)	Female	1	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	12	11.6	103.6	(53.4-180.9)	<u>Ovary</u>				
Female	9	9.1	98.4	(44.9-186.8)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	29	31.8	91.3	(61.1-131.1)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.9	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	6	2.0	307.5	(112.3-669.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	3.8	184.1	(73.8-379.4)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.9	nc	(nc-nc)	Female	6	6.1	98.8	(36.1-214.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	103	107.1	96.1	(78.5-116.6)
Female	1	0.5	nc	(nc-nc)	Female	118	93.5	126.1	(104.4-151.1)
<u>Lung and Bronchus</u>									
Male	9	14.3	62.9	(28.7-119.4)					
Female	7	11.6	60.2	(24.1-124.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				
Male	22	18.6	118.4	(74.2-179.2)
Female	5	7.5	66.5	(21.4-155.2)
<u>Brain and Other Nervous System</u>				
Male	5	3.5	141.6	(45.6-330.5)
Female	3	3.1	nc	(nc-nc)
<u>Breast</u>				
Male	0	0.5	nc	(nc-nc)
Female	51	70.0	72.8	(54.2-95.8)
<u>Cervix Uteri</u>				
Female	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>				
Male	29	27.6	105.2	(70.5-151.1)
Female	31	30.3	102.2	(69.4-145.1)
<u>Esophagus</u>				
Male	0	4.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>				
Male	5	7.5	66.5	(21.4-155.2)
Female	3	5.2	nc	(nc-nc)
<u>Larynx</u>				
Male	6	3.0	203.1	(74.2-442.2)
Female	2	0.9	nc	(nc-nc)
<u>Leukemia</u>				
Male	4	5.9	nc	(nc-nc)
Female	6	5.3	112.3	(41.0-244.3)
<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	3.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
<u>Lung and Bronchus</u>				
Male	36	33.9	106.3	(74.4-147.1)
Female	27	34.5	78.2	(51.5-113.7)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Melanoma of Skin</u>				
Male	10	10.2	98.4	(47.1-181.1)
Female	5	8.9	56.1	(18.1-130.9)
<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)
<u>Non-Hodgkin Lymphoma</u>				
Male	7	9.5	74.0	(29.7-152.5)
Female	9	9.6	94.1	(42.9-178.6)
<u>Oral Cavity & Pharynx</u>				
Male	10	6.6	150.4	(72.0-276.7)
Female	3	3.5	nc	(nc-nc)
<u>Ovary</u>				
Female	9	7.7	117.0	(53.4-222.1)
<u>Pancreas</u>				
Male	6	5.2	115.7	(42.2-251.8)
Female	4	6.5	nc	(nc-nc)
<u>Prostate</u>				
Male	53	68.8	77.0	(57.7-100.7)
<u>Stomach</u>				
Male	2	4.7	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)
<u>Testis</u>				
Male	4	2.6	nc	(nc-nc)
<u>Thyroid</u>				
Male	2	2.1	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)
<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	14.3	146.6	(90.7-224.1)
<u>All Sites / Types</u>				
Male	219	240.3	91.1	(79.5-104.0)
Female	208	247.5	84.0	(73.0-96.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.2	76.2	(30.5-157.0)	Male	4	5.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	5	4.3	116.4	(37.5-271.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	4.9	181.9	(83.0-345.4)
Female	42	34.1	123.1	(88.7-166.4)	Female	5	4.2	120.0	(38.7-280.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.6	nc	(nc-nc)
Male	11	13.9	79.3	(39.5-141.9)	<u>Ovary</u>				
Female	18	12.4	145.6	(86.3-230.2)	Female	4	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	5	2.6	190.5	(61.4-444.6)
Female	0	0.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	30	35.6	84.4	(56.9-120.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.4	211.8	(68.2-494.2)
Male	1	4.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.8	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	119	123.4	96.4	(79.9-115.4)
Female	0	0.6	nc	(nc-nc)	Female	106	112.6	94.1	(77.1-113.9)
<u>Lung and Bronchus</u>									
Male	24	17.0	140.9	(90.2-209.6)					
Female	13	15.2	85.5	(45.5-146.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	12.5	47.8	(17.5-104.1)	Male	9	7.3	124.1	(56.6-235.5)
Female	7	4.2	168.4	(67.5-347.0)	Female	6	5.7	106.0	(38.7-230.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	6.6	136.5	(62.3-259.0)
Female	44	45.1	97.5	(70.8-130.9)	Female	7	5.5	126.9	(50.9-261.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	5	5.0	100.6	(32.4-234.8)
<u>Colon / Rectum</u>					Female	6	2.1	279.7	(102.1-608.8)
Male	19	19.0	100.1	(60.2-156.3)	<u>Ovary</u>				
Female	14	16.3	85.8	(46.9-144.0)	Female	4	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	31	50.2	61.7	(41.9-87.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.2	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	6	3.2	189.8	(69.3-413.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	1.6	317.3	(102.3-740.6)
<u>Leukemia</u>					Female	5	5.0	100.6	(32.4-234.7)
Male	1	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.0	197.7	(72.2-430.3)	Female	14	9.4	149.6	(81.7-251.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.7	nc	(nc-nc)	Male	137	169.7	80.7	(67.8-95.4)
Female	0	0.8	nc	(nc-nc)	Female	160	149.1	107.3	(91.3-125.3)
<u>Lung and Bronchus</u>									
Male	25	23.6	106.0	(68.6-156.6)					
Female	24	20.3	118.2	(75.7-175.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

288

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	118	137.3	85.9	(71.1-102.9)	Male	42	76.8	54.7	(39.4-73.9)
Female	35	55.1	63.5	(44.2-88.4)	Female	22	71.0	31.0	(19.4-46.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	28.2	70.9	(43.3-109.6)	Male	16	20.6	77.5	(44.3-125.9)
Female	21	25.4	82.8	(51.2-126.5)	Female	17	17.5	97.2	(56.6-155.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	4.1	nc	(nc-nc)	Male	56	71.5	78.4	(59.2-101.8)
Female	509	547.0	93.1	(85.1-101.5)	Female	67	71.7	93.5	(72.4-118.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	41	25.3	162.2	(116.4-220.1)	Male	52	49.9	104.3	(77.9-136.8)
<u>Colon / Rectum</u>					Female	22	27.1	81.2	(50.9-122.9)
Male	182	204.1	89.2	(76.7-103.1)	<u>Ovary</u>				
Female	206	218.2	94.4	(82.0-108.2)	Female	42	59.7	70.4	(50.7-95.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	41	34.3	119.6	(85.8-162.3)	Male	38	38.5	98.8	(69.9-135.6)
Female	8	10.7	74.7	(32.2-147.1)	Female	42	46.7	89.9	(64.8-121.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	12.9	70.0	(31.9-132.9)	Male	473	516.1	91.7	(83.6-100.3)
Female	11	11.9	92.7	(46.2-165.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	50	35.0	142.7	(105.9-188.2)
Male	53	56.6	93.7	(70.2-122.6)	Female	34	23.5	144.8	(100.3-202.3)
Female	43	40.0	107.5	(77.8-144.7)	<u>Testis</u>				
<u>Larynx</u>					Male	29	22.3	130.2	(87.2-187.0)
Male	29	22.1	131.3	(87.9-188.6)	<u>Thyroid</u>				
Female	5	6.8	73.0	(23.5-170.4)	Male	5	16.5	30.3	(9.8-70.8)
<u>Leukemia</u>					Female	51	61.0	83.6	(62.2-109.9)
Male	34	45.9	74.1	(51.3-103.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	40	40.9	97.8	(69.9-133.2)	Female	134	112.5	119.1	(99.8-141.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	26	27.3	95.1	(62.1-139.3)	Male	1612	1803.4	89.4	(85.1-93.9)
Female	7	11.1	62.9	(25.2-129.7)	Female	1763	1888.7	93.3	(89.0-97.8)
<u>Lung and Bronchus</u>									
Male	221	252.8	87.4	(76.3-99.7)					
Female	260	260.1	100.0	(88.2-112.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

289

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.0	99.8	(40.0-205.7)	Male	2	4.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.9	179.0	(71.7-368.9)
Female	25	26.8	93.4	(60.4-137.8)	Female	5	2.9	171.1	(55.1-399.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	9	10.9	82.8	(37.8-157.3)	<u>Ovary</u>				
Female	3	8.2	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	32	29.0	110.2	(75.4-155.6)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.3	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.6	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	88	98.5	89.4	(71.7-110.1)
Female	0	0.4	nc	(nc-nc)	Female	76	82.8	91.8	(72.3-114.9)
<u>Lung and Bronchus</u>									
Male	6	13.3	45.0	(16.4-97.9)					
Female	8	10.3	77.4	(33.3-152.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

290

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.2	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	9	13.2	68.4	(31.2-129.8)	Female	2	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	6.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	5.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	13	15.5	83.7	(44.5-143.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	44	52.2	84.2	(61.2-113.1)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	7.7	91.2	(36.5-188.0)					

Female	4	6.6	nc	(nc-nc)	Female	36	45.2	79.7	(55.8-110.3)
--------	---	-----	----	---------	--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

291

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	29.6	121.4	(85.0-168.1)	Male	10	15.5	64.5	(30.9-118.7)
Female	14	11.6	120.3	(65.7-201.9)	Female	12	13.0	92.0	(47.5-160.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	137.8	(55.2-283.9)	Male	6	4.4	136.2	(49.8-296.6)
Female	4	4.5	nc	(nc-nc)	Female	5	3.7	135.8	(43.8-316.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	14.5	83.0	(42.9-145.1)
Female	116	106.6	108.8	(89.9-130.5)	Female	11	14.5	76.1	(37.9-136.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.5	178.7	(76.9-352.1)	Male	10	10.3	97.3	(46.6-179.0)
<u>Colon / Rectum</u>					Female	7	5.4	130.3	(52.2-268.4)
Male	51	43.6	117.0	(87.1-153.8)	<u>Ovary</u>				
Female	56	46.3	120.9	(91.3-157.0)	Female	19	11.7	162.9	(98.0-254.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.3	96.0	(38.5-197.8)	Male	8	8.2	97.2	(41.9-191.6)
Female	3	2.3	nc	(nc-nc)	Female	16	9.9	160.9	(91.9-261.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	137	111.3	123.0	(103.3-145.5)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	7.5	nc	(nc-nc)
Male	18	11.7	153.3	(90.8-242.3)	Female	7	5.0	138.7	(55.6-285.8)
Female	10	8.0	125.3	(60.0-230.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.2	nc	(nc-nc)
Male	8	4.7	170.2	(73.3-335.5)	<u>Thyroid</u>				
Female	3	1.4	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.1	109.3	(54.5-195.6)
Male	10	8.9	112.4	(53.8-206.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.9	75.9	(27.7-165.2)	Female	10	22.1	45.3	(21.7-83.3)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	8	5.7	140.3	(60.4-276.6)					
Female	1	2.3	nc	(nc-nc)					

Lung and Bronchus

Male	53	54.4	97.4	(73.0-127.4)
Female	70	53.8	130.1	(101.5-164.4)

All Sites / Types

Male	419	378.7	110.6	(100.3-121.8)
Female	423	375.9	112.5	(102.1-123.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

292

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.2	112.3	(78.2-156.1)	Male	25	17.4	144.1	(93.2-212.7)
Female	9	12.1	74.4	(34.0-141.3)	Female	18	14.8	121.3	(71.9-191.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.9	84.4	(27.2-197.0)	Male	11	4.7	232.6	(116.0-416.3)
Female	4	5.1	nc	(nc-nc)	Female	8	3.8	208.3	(89.7-410.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	15	15.9	94.1	(52.6-155.3)
Female	117	121.0	96.7	(80.0-115.9)	Female	10	15.4	64.9	(31.0-119.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.3	170.9	(78.0-324.4)	Male	17	11.8	143.6	(83.6-229.9)
<u>Colon / Rectum</u>					Female	8	5.9	135.4	(58.3-266.7)
Male	45	46.7	96.3	(70.2-128.8)	<u>Ovary</u>				
Female	51	47.5	107.4	(80.0-141.3)	Female	18	13.0	138.0	(81.7-218.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	8.0	199.9	(114.2-324.7)	Male	6	8.9	67.6	(24.7-147.2)
Female	4	2.3	nc	(nc-nc)	Female	14	10.2	137.2	(75.0-230.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	143	123.2	116.1	(97.9-136.8)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.9	88.5	(35.5-182.4)
Male	10	13.2	75.7	(36.3-139.3)	Female	1	5.1	nc	(nc-nc)
Female	8	8.7	91.8	(39.5-181.0)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.0	151.1	(55.2-328.9)
Male	5	5.2	95.8	(30.9-223.6)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	5	3.6	137.1	(44.2-319.9)
<u>Leukemia</u>					Female	13	12.2	106.7	(56.8-182.5)
Male	8	9.8	81.7	(35.2-160.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.4	83.8	(33.6-172.6)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	3	6.4	nc	(nc-nc)					
Female	3	2.4	nc	(nc-nc)	Female	28	25.3	110.5	(73.4-159.7)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	55	58.4	94.1	(70.9-122.5)	Male	451	414.4	108.8	(99.0-119.3)
Female	65	57.5	113.0	(87.2-144.0)	Female	443	410.7	107.9	(98.1-118.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

293

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	6	3.4	176.1	(64.3-383.2)
Female	3	1.7	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.0	201.4	(73.5-438.3)
Female	23	22.6	101.7	(64.5-152.7)	Female	0	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	5	8.1	61.4	(19.8-143.2)	<u>Ovary</u>				
Female	7	6.8	102.6	(41.1-211.3)	Female	0	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	30	23.6	127.3	(85.9-181.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>									
Male	0	1.8	nc	(nc-nc)					

Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Lung and Bronchus

Male	8	10.1	79.1	(34.1-155.9)
Female	5	8.7	57.3	(18.5-133.7)

Female	0	2.7	nc	(nc-nc)
<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.7	nc	(nc-nc)

All Sites / Types

Male	71	76.5	92.8	(72.5-117.1)
Female	58	69.5	83.5	(63.4-108.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

294

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.6	124.7	(64.4-217.8)	Male	0	5.4	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	141.2	(56.6-290.9)
Female	23	34.0	67.6	(42.9-101.5)	Female	4	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	12	14.5	82.7	(42.7-144.5)	<u>Ovary</u>				
Female	9	12.5	72.2	(33.0-137.1)	Female	3	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	38.3	62.7	(40.2-93.3)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.5	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

Leukemia

Male	4	3.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	2.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Lung and Bronchus

Male	19	18.1	105.2	(63.3-164.2)
Female	16	15.5	103.5	(59.1-168.2)

Thyroid

Male	2	1.1	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	6	7.0	85.3	(31.2-185.7)
--------	---	-----	------	--------------

All Sites / Types

Male	102	128.8	79.2	(64.6-96.1)
Female	90	112.4	80.0	(64.4-98.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

295

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.9	107.1	(62.3-171.5)	Male	14	9.8	142.6	(77.9-239.2)
Female	6	5.2	115.2	(42.1-250.8)	Female	13	7.8	167.4	(89.1-286.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.6	222.9	(96.0-439.3)	Male	2	2.5	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	8.8	182.6	(104.3-296.5)
Female	89	63.8	139.5	(112.0-171.6)	Female	8	7.0	113.5	(48.9-223.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	5	7.1	70.7	(22.8-165.1)
<u>Colon / Rectum</u>					Female	5	2.9	173.9	(56.1-405.9)
Male	22	24.5	89.7	(56.2-135.9)	<u>Ovary</u>				
Female	28	20.5	136.6	(90.8-197.5)	Female	5	6.6	75.3	(24.3-175.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.4	nc	(nc-nc)	Male	8	4.7	171.1	(73.7-337.2)
Female	1	1.0	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	71	68.2	104.1	(81.3-131.4)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.1	172.0	(68.9-354.3)
Male	3	7.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>									

Male	1	2.9	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	5.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	8	7.2	111.5	(48.0-219.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.7	nc	(nc-nc)	Female	11	13.1	84.0	(41.9-150.4)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	22	30.6	71.8	(45.0-108.8)	Male	227	225.0	100.9	(88.2-114.9)
Female	18	25.5	70.6	(41.8-111.6)	Female	227	199.7	113.7	(99.3-129.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

296

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	11	10.3	106.4	(53.0-190.3)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
					Female	2	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	5	3.9	127.9	(41.2-298.5)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	9.4	127.4	(65.8-222.5)
Female	0	0.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)

Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	4.5	nc	(nc-nc)	Male	24	34.2	70.2	(45.0-104.5)
Female	3	4.4	nc	(nc-nc)	Female	30	35.3	84.9	(57.3-121.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

297

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.4	68.0	(21.9-158.6)	Male	3	4.8	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.2	119.1	(38.4-277.9)
Female	23	28.4	80.9	(51.3-121.4)	Female	3	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	11	11.5	95.8	(47.8-171.4)	<u>Ovary</u>				
Female	6	8.5	70.3	(25.7-152.9)	Female	5	2.9	169.5	(54.6-395.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	31.1	77.1	(49.4-114.7)
Female	1	0.6	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	5	3.5	141.0	(45.4-329.0)
Female	2	1.8	nc	(nc-nc)

Larynx

Male	3	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Leukemia

Male	5	2.6	194.5	(62.7-453.9)
Female	2	1.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Lung and Bronchus

Male	9	14.0	64.4	(29.4-122.2)
Female	13	11.0	118.4	(63.0-202.4)

Stomach

Male	1	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Testis

Male	4	1.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	1.1	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	5	5.8	86.4	(27.9-201.7)
--------	---	-----	------	--------------

All Sites / Types

Male	91	105.2	86.5	(69.7-106.2)
Female	80	88.0	90.9	(72.1-113.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

298

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	19.3	98.2	(59.1-153.4)	Male	26	10.1	258.3	(168.7-378.5)
Female	9	7.6	119.0	(54.3-225.9)	Female	15	8.5	175.4	(98.1-289.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	5	2.9	173.8	(56.0-405.6)
Female	2	3.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.4	117.0	(58.3-209.4)
Female	73	70.5	103.6	(81.2-130.3)	Female	11	9.4	116.6	(58.1-208.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	20	28.4	70.4	(43.0-108.8)	<u>Ovary</u>				
Female	32	30.9	103.7	(70.9-146.4)	Female	14	7.7	182.3	(99.6-305.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.7	nc	(nc-nc)	Male	9	5.4	167.9	(76.6-318.7)
Female	0	1.5	nc	(nc-nc)	Female	9	6.5	137.6	(62.8-261.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	2	1.2	nc	(nc-nc)	Male	70	70.0	100.0	(77.9-126.3)
Female	0	1.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	9	7.5	119.4	(54.5-226.7)	Male	1	4.9	nc	(nc-nc)
Female	8	5.2	155.1	(66.8-305.6)	Female	2	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	3.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	13	5.8	224.8	(119.6-384.4)	Male	3	1.9	nc	(nc-nc)
Female	10	5.3	189.6	(90.8-348.6)	Female	7	6.6	105.6	(42.3-217.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.7	nc	(nc-nc)					
Female	1	1.5	nc	(nc-nc)	Female	13	14.3	90.7	(48.2-155.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	28	34.5	81.0	(53.8-117.1)	Male	253	243.0	104.1	(91.7-117.8)
Female	26	34.1	76.3	(49.8-111.8)	Female	263	246.6	106.7	(94.2-120.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

299

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	20.1	114.5	(72.6-171.8)	Male	10	11.1	90.4	(43.3-166.3)
Female	9	7.3	124.1	(56.6-235.6)	Female	7	8.8	79.2	(31.7-163.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	6	3.0	198.8	(72.6-432.7)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	10.2	88.3	(40.3-167.7)
Female	56	72.8	76.9	(58.1-99.9)	Female	11	9.2	119.0	(59.3-212.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	6	7.6	78.9	(28.8-171.8)
Female	4	3.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	30.1	119.7	(83.8-165.8)					
Female	38	28.5	133.3	(94.3-183.0)	Female	3	7.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.1	97.4	(31.4-227.4)	Male	3	5.7	nc	(nc-nc)

Female	0	1.4	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	2	1.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)

Kidney & Renal Pelvis

Male	4	8.4	nc	(nc-nc)
Female	8	5.2	152.7	(65.8-300.9)

Larynx

Male	3	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Leukemia

Male	4	6.2	nc	(nc-nc)
Female	4	5.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	6	4.1	145.9	(53.3-317.5)
Female	2	1.4	nc	(nc-nc)

Lung and Bronchus

Male	59	37.4	157.7	(120.0-203.4)
Female	22	34.7	63.4	(39.7-96.0)

Female	4	6.1	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	82	78.7	104.2	(82.9-129.4)
------	----	------	-------	--------------

Stomach

Male	4	5.1	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)

Testis

Male	1	2.4	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	3	2.3	nc	(nc-nc)
Female	9	7.2	125.2	(57.1-237.7)

Uteri Corpus and Uterus, NOS

Female	17	15.2	111.8	(65.1-178.9)
--------	----	------	-------	--------------

All Sites / Types

Male	286	265.1	107.9	(95.7-121.1)
Female	229	246.4	92.9	(81.3-105.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

300

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				
Male	76	54.6	139.1	(109.6-174.2)
Female	19	21.4	88.8	(53.4-138.7)

Brain and Other Nervous System

Male	6	11.1	53.9	(19.7-117.3)
Female	8	9.6	83.1	(35.8-163.7)

Breast

Male	2	1.7	nc	(nc-nc)
Female	193	214.4	90.0	(77.8-103.7)

Cervix Uteri

Female	9	10.0	89.7	(40.9-170.3)
--------	---	------	------	--------------

Colon / Rectum

Male	82	82.1	99.9	(79.5-124.0)
Female	86	85.1	101.0	(80.8-124.8)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Melanoma of Skin</u>				
Male	15	31.6	47.5	(26.6-78.4)
Female	22	27.8	79.3	(49.7-120.0)

Multiple Myeloma

Male	10	8.3	120.1	(57.5-220.8)
Female	8	6.8	117.9	(50.8-232.4)

Non-Hodgkin Lymphoma

Male	26	28.8	90.2	(58.9-132.1)
Female	30	27.9	107.7	(72.6-153.7)

Oral Cavity & Pharynx

Male	22	20.9	105.3	(66.0-159.4)
Female	13	10.5	123.4	(65.7-211.1)

Ovary

Female	17	23.2	73.2	(42.6-117.1)
--------	----	------	------	--------------

Esophagus

Male	10	14.0	71.4	(34.2-131.4)
Female	6	4.2	144.5	(52.8-314.5)

Hodgkin Lymphoma

Male	5	4.9	102.0	(32.9-237.9)
Female	2	4.3	nc	(nc-nc)

Kidney & Renal Pelvis

Male	33	23.4	140.9	(97.0-197.9)
Female	15	15.5	96.9	(54.2-159.9)

Larynx

Male	16	9.1	175.4	(100.2-284.9)
Female	4	2.7	nc	(nc-nc)

Leukemia

Male	11	17.9	61.3	(30.6-109.7)
Female	19	15.6	121.5	(73.1-189.7)

Liver and Intrahepatic Bile Ducts

Male	10	11.3	88.6	(42.4-163.0)
Female	2	4.3	nc	(nc-nc)

Lung and Bronchus

Male	132	102.1	129.3	(108.2-153.3)
Female	106	100.6	105.4	(86.3-127.5)

Pancreas

Male	15	15.5	96.7	(54.1-159.5)
Female	23	18.2	126.7	(80.3-190.1)

Prostate

Male	219	213.9	102.4	(89.3-116.9)
------	-----	-------	-------	--------------

Stomach

Male	25	14.0	178.7	(115.6-263.8)
Female	13	9.2	141.4	(75.2-241.8)

Testis

Male	7	9.0	78.2	(31.3-161.1)
------	---	-----	------	--------------

Thyroid

Male	5	7.0	71.6	(23.1-167.0)
Female	26	23.9	108.8	(71.1-159.5)

Uteri Corpus and Uterus, NOS

Female	40	44.0	90.8	(64.9-123.7)
--------	----	------	------	--------------

All Sites / Types

Male	793	733.1	108.2	(100.8-116.0)
Female	700	735.5	95.2	(88.3-102.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

301

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.5	79.5	(29.0-173.1)	Male	6	4.4	135.2	(49.4-294.3)
Female	2	2.6	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	20	26.9	74.3	(45.4-114.7)	Female	5	3.4	148.1	(47.7-345.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
					<u>Ovary</u>				

Male	11	11.5	95.7	(47.7-171.3)				
Female	9	10.3	87.3	(39.8-165.7)	Female	7	2.9	242.0 (97.0-498.7)
<u>Esophagus</u>					<u>Pancreas</u>			
Male	2	2.0	nc	(nc-nc)	Male	1	2.2	nc (nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.2	nc (nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>			
Male	0	0.6	nc	(nc-nc)	Male	37	30.6	120.9 (85.1-166.6)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>			
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc (nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	2	1.1	nc (nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Testis</u>			
<u>Larynx</u>					Male	0	1.1	nc (nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>			
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc (nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc (nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>			
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>			
<u>Liver and Intrahepatic Bile Ducts</u>					Female	10	5.5	181.4 (86.8-333.6)
Male	1	1.6	nc	(nc-nc)	Male	106	103.1	102.8 (84.2-124.3)
Female	0	0.5	nc	(nc-nc)	Female	91	90.6	100.4 (80.9-123.3)
<u>Lung and Bronchus</u>								
Male	22	14.3	154.0	(96.5-233.2)				
Female	15	12.3	121.6	(68.0-200.6)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

302

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	28.5	87.7	(56.7-129.5)	Male	15	17.2	87.5	(48.9-144.3)
Female	18	10.1	178.1	(105.5-281.5)	Female	19	14.2	134.0	(80.6-209.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	6.0	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	5	4.9	102.5	(33.0-239.2)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	15.4	110.3	(64.2-176.6)
Female	104	113.3	91.8	(75.0-111.2)	Female	19	13.4	141.5	(85.2-221.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	12	11.9	101.1	(52.2-176.7)

Female	9	5.3	168.7	(77.0-320.3)
<u>Colon / Rectum</u>				
Male	44	43.5	101.1	(73.5-135.8)
Female	50	39.1	127.9	(94.9-168.6)
<u>Esophagus</u>				
Male	6	7.6	78.9	(28.8-171.6)
Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>				
Male	5	2.5	199.8	(64.4-466.2)
Female	3	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>				
Male	15	13.0	115.8	(64.8-191.0)
Female	8	7.8	102.4	(44.1-201.7)
<u>Larynx</u>				
Male	4	5.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
<u>Leukemia</u>				
Male	7	9.5	74.0	(29.7-152.6)
Female	10	7.4	135.8	(65.0-249.8)
<u>Liver and Intrahepatic Bile Ducts</u>				
Male	12	6.3	190.9	(98.5-333.4)
Female	1	2.1	nc	(nc-nc)
<u>Lung and Bronchus</u>				
Male	67	54.5	123.0	(95.3-156.2)
Female	59	49.8	118.4	(90.1-152.7)

Female	7	5.3	131.9	(52.9-271.8)
<u>Ovary</u>				
Female	10	12.0	83.4	(39.9-153.4)
<u>Pancreas</u>				
Male	11	8.3	132.9	(66.3-237.9)
Female	4	8.4	nc	(nc-nc)
<u>Prostate</u>				
Male	115	119.1	96.6	(79.7-115.9)
<u>Stomach</u>				
Male	2	7.3	nc	(nc-nc)
Female	5	4.1	122.8	(39.6-286.5)
<u>Testis</u>				
Male	9	4.5	199.1	(90.9-378.1)
<u>Thyroid</u>				
Male	5	3.9	128.3	(41.3-299.3)
Female	15	12.7	118.3	(66.2-195.2)
<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	23.7	84.4	(51.6-130.4)
<u>All Sites / Types</u>				
Male	399	396.3	100.7	(91.0-111.1)
Female	400	368.5	108.6	(98.2-119.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

303

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.8	nc	(nc-nc)	Male	6	2.5	235.6	(86.0-512.9)
Female	1	2.1	nc	(nc-nc)	Female	9	2.3	385.5	(175.9-731.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	23	19.4	118.8	(75.3-178.3)	Female	1	2.6	nc	(nc-nc)

Cervix Uteri

Female	3	0.8	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	4	7.0	nc	(nc-nc)
Female	6	8.4	71.5	(26.1-155.7)

Esophagus

Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Kidney & Renal Pelvis

Male	1	1.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)

Larynx

Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Leukemia

Male	1	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Lung and Bronchus

Male	15	8.7	173.2	(96.9-285.7)
Female	12	9.7	124.1	(64.0-216.7)

Oral Cavity & Pharynx

Male	2	1.7	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)

Ovary

Female	3	2.1	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	1.3	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

Prostate

Male	20	17.5	114.0	(69.6-176.1)
------	----	------	-------	--------------

Stomach

Male	2	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Testis

Male	0	0.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.5	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	3	4.0	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	69	60.8	113.5	(88.3-143.6)
Female	78	67.9	114.9	(90.8-143.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

304

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.2	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

305

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.1	nc	(nc-nc)	Male	5	4.3	115.2	(37.1-268.8)
Female	3	2.6	nc	(nc-nc)	Female	5	3.2	154.1	(49.7-359.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)

Female	4	1.1	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	28	27.3	102.7	(68.2-148.5)

Cervix Uteri

Female	4	1.2	nc	(nc-nc)
Colon / Rectum				
Male	9	12.0	75.0	(34.2-142.4)
Female	22	10.3	213.8	(133.9-323.7)

Esophagus

Male	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	0	3.4	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)

Larynx

Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Leukemia

Male	2	2.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Lung and Bronchus

Male	12	15.1	79.7	(41.1-139.3)
Female	7	12.6	55.4	(22.2-114.1)

Female	2	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	4.0	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)

Oral Cavity & Pharynx

Male	3	3.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

Ovary

Female	6	2.9	206.4	(75.4-449.2)
--------	---	-----	-------	--------------

Pancreas

Male	1	2.3	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)

Prostate

Male	38	31.6	120.3	(85.1-165.1)
------	----	------	-------	--------------

Stomach

Male	3	2.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)

Testis

Male	1	0.8	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.9	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	4	5.6	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	90	105.6	85.2	(68.5-104.8)
Female	107	90.7	117.9	(96.6-142.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

306

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.1	179.8	(89.7-321.8)	Male	4	4.4	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)

Brain and Other Nervous System

Male	1	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

Breast

Male	0	0.2	nc	(nc-nc)
Female	32	29.0	110.2	(75.3-155.5)

Cervix Uteri

Female	1	1.5	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	9	9.8	92.0	(42.0-174.7)
Female	9	8.7	103.1	(47.0-195.7)

Esophagus

Male	2	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Kidney & Renal Pelvis

Male	4	3.2	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)

Larynx

Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Leukemia

Male	2	2.3	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Lung and Bronchus

Male	13	11.8	109.9	(58.5-187.9)
Female	17	11.0	154.9	(90.2-248.0)

Multiple Myeloma

Male	1	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	4	3.8	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)

Oral Cavity & Pharynx

Male	3	3.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

Ovary

Female	3	3.0	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	3	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)

Prostate

Male	31	26.4	117.2	(79.6-166.4)
------	----	------	-------	--------------

Stomach

Male	1	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Testis

Male	2	1.4	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	1.1	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	7	5.7	122.5	(49.1-252.5)
--------	---	-----	-------	--------------

All Sites / Types

Male	97	91.6	105.9	(85.9-129.2)
Female	93	89.6	103.8	(83.7-127.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	4	3.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	7	1.3	528.5	(211.8-1089.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	11	11.2	98.1	(48.9-175.5)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	17	12.4	136.7	(79.6-218.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	53	41.6	127.5	(95.5-166.7)
Female	0	0.2	nc	(nc-nc)	Female	37	36.7	100.9	(71.1-139.1)
<u>Lung and Bronchus</u>									
Male	9	6.0	150.9	(68.9-286.5)					
Female	5	5.1	97.8	(31.5-228.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				
Male	11	7.4	149.3	(74.4-267.2)
Female	5	2.6	195.3	(62.9-455.8)
<u>Brain and Other Nervous System</u>				
Male	5	2.0	249.4	(80.4-582.1)
Female	1	1.6	nc	(nc-nc)
<u>Breast</u>				
Male	1	0.2	nc	(nc-nc)
Female	40	33.7	118.6	(84.7-161.5)
<u>Cervix Uteri</u>				
Female	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>				
Male	16	11.6	137.5	(78.5-223.3)
Female	10	10.1	98.9	(47.3-181.9)
<u>Esophagus</u>				
Male	2	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>				
Male	1	3.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
<u>Larynx</u>				
Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>				
Male	2	2.8	nc	(nc-nc)
Female	6	2.2	274.3	(100.2-597.1)
<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
<u>Lung and Bronchus</u>				
Male	19	14.1	134.5	(81.0-210.1)
Female	15	12.8	117.2	(65.6-193.4)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Melanoma of Skin</u>				
Male	1	5.2	nc	(nc-nc)
Female	6	4.6	131.8	(48.1-286.9)
<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
<u>Non-Hodgkin Lymphoma</u>				
Male	3	4.5	nc	(nc-nc)
Female	5	3.7	134.3	(43.3-313.3)
<u>Oral Cavity & Pharynx</u>				
Male	5	3.5	141.9	(45.7-331.2)
Female	0	1.5	nc	(nc-nc)
<u>Ovary</u>				
Female	5	3.5	142.9	(46.0-333.5)
<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)
Female	6	2.1	283.5	(103.5-617.1)
<u>Prostate</u>				
Male	39	30.8	126.7	(90.1-173.2)
<u>Stomach</u>				
Male	0	2.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)
<u>Testis</u>				
Male	3	1.8	nc	(nc-nc)
<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)
Female	6	4.6	130.7	(47.7-284.4)
<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.7	119.8	(51.6-236.1)
<u>All Sites / Types</u>				
Male	123	108.3	113.5	(94.3-135.4)
Female	123	104.9	117.2	(97.4-139.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.8	64.4	(20.8-150.3)
Female	0	0.0	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

310
Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	28	20.9	134.0	(89.0-193.7)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	7.4	nc	(nc-nc)	<u>Ovary</u>				
Female	13	7.3	178.3	(94.8-304.8)	Female	4	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	26	19.8	131.6	(86.0-192.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	6	2.3	259.6	(94.8-565.0)	Female	1	0.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.5	nc	(nc-nc)	Female	5	4.1	121.3	(39.1-283.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	66	68.0	97.0	(75.0-123.4)
Female	0	0.4	nc	(nc-nc)	Female	85	67.9	125.2	(100.0-154.8)
<u>Lung and Bronchus</u>									
Male	8	9.0	88.6	(38.2-174.7)					
Female	7	8.7	80.7	(32.3-166.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

311

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	9.1	207.8	(125.1-324.5)	Male	6	5.8	102.7	(37.5-223.6)
Female	5	3.6	138.7	(44.7-323.7)	Female	3	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.2	114.7	(41.9-249.7)
Female	43	39.7	108.2	(78.3-145.7)	Female	6	4.8	123.7	(45.2-269.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	18	14.1	128.1	(75.9-202.4)	<u>Ovary</u>				
Female	18	14.3	126.2	(74.7-199.4)	Female	2	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	43	37.1	115.7	(83.8-155.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	5	2.7	182.0	(58.7-424.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.8	123.8	(45.2-269.4)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	8	7.9	100.9	(43.5-198.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.1	nc	(nc-nc)	Male	150	128.6	116.6	(98.7-136.8)
Female	2	0.7	nc	(nc-nc)	Female	141	131.3	107.4	(90.4-126.6)
<u>Lung and Bronchus</u>									
Male	23	17.4	132.0	(83.7-198.1)					
Female	18	17.2	104.4	(61.9-165.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

312

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	28.1	85.3	(54.7-127.0)	Male	16	15.6	102.2	(58.4-166.0)
Female	16	11.2	142.8	(81.6-231.9)	Female	18	13.5	133.1	(78.8-210.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.3	nc	(nc-nc)	Male	8	4.2	188.7	(81.3-371.9)
Female	3	4.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	17	14.4	118.2	(68.8-189.2)
Female	92	108.2	85.1	(68.6-104.3)	Female	16	14.2	112.3	(64.1-182.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.8	145.6	(58.3-299.9)	Male	5	10.4	47.9	(15.4-111.8)
<u>Colon / Rectum</u>					Female	2	5.4	nc	(nc-nc)
Male	41	41.9	97.8	(70.2-132.7)	<u>Ovary</u>				
Female	49	44.9	109.0	(80.6-144.1)	Female	14	11.7	119.3	(65.2-200.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.1	nc	(nc-nc)	Male	8	7.9	101.0	(43.5-198.9)
Female	0	2.2	nc	(nc-nc)	Female	6	9.6	62.6	(22.9-136.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	131	107.7	121.7	(101.7-144.4)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	7.1	nc	(nc-nc)
Male	13	11.8	110.6	(58.8-189.2)	Female	6	4.9	122.4	(44.7-266.5)
Female	7	7.9	88.8	(35.6-182.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.8	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	7	3.3	212.1	(85.0-437.0)
<u>Leukemia</u>					Female	15	11.0	135.8	(75.9-223.9)
Male	12	8.8	136.0	(70.2-237.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	7.9	138.9	(69.2-248.6)	Female	20	22.0	90.7	(55.4-140.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	5.7	175.0	(83.8-321.9)	Male	375	369.2	101.6	(91.6-112.4)
Female	2	2.3	nc	(nc-nc)	Female	366	374.3	97.8	(88.0-108.3)
<u>Lung and Bronchus</u>									
Male	36	52.2	68.9	(48.3-95.4)					
Female	48	51.9	92.5	(68.2-122.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

313

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	9	6.4	139.5	(63.7-264.9)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.8	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	6.5	168.9	(84.2-302.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	26	21.1	123.2	(80.5-180.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	2.7	nc	(nc-nc)					

Female	2	2.4	nc	(nc-nc)	Female	19	19.4	97.8	(58.8-152.7)
--------	---	-----	----	---------	--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;